Short Interest in CapsoVision, Inc. (NASDAQ:CV) Grows By 35.2%

CapsoVision, Inc. (NASDAQ:CV - Get Free Report) saw a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 553,348 shares, a growth of 35.2% from the February 26th total of 409,160 shares. Based on an average daily volume of 199,118 shares, the days-to-cover ratio is currently 2.8 days. Approximately 1.2% of the company's shares are sold short.Analysts Set New Price Targets3 Under-the-Radar Software Stocks Ready to BounceA number of equities analysts recently issued reports on the company. Wall Street Zen upgraded CapsoVision to a "hold" rating in a report on Saturday, January 10th. Weiss Ratings reiterated a "sell (e)" rating on shares of CapsoVision in a research report on Monday, December 29th. Finally, Benchmark lowered their target price on shares of CapsoVision from $14.00 to $10.00 and set a "speculative buy" rating for the company in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $8.50.Read Our Latest Analysis on CVCapsoVision Trading Down 0.3%Hidden Gems: 3 Value Stocks to Watch for Strong 2025 ReturnsShares of NASDAQ CV traded down $0.02 during trading hours on Friday, reaching $7.51. The stock had a trading volume of 288,209 shares, compared to its average volume of 578,162. CapsoVision has a 52-week low of $3.43 and a 52-week high of $15.37. The firm has a market cap of $351.77 million and a price-to-earnings ratio of -3.43. The business's fifty day moving average price is $5.58 and its two-hundred day moving average price is $6.27. CapsoVision (NASDAQ:CV - Get Free Report) last released its quarterly earnings data on Thursday, March 26th. The company reported $0.02 EPS for the quarter. The firm had revenue of $3.92 million for the quarter. Hedge Funds Weigh In On CapsoVision2 Small-Cap Stocks Set to Shine in a Bull MarketSeveral institutional investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in shares of CapsoVision in the fourth quarter valued at about $128,000. Millennium Management LLC bought a new position in CapsoVision during the 4th quarter worth about $163,000. State Street Corp grew its holdings in CapsoVision by 340.7% during the 4th quarter. State Street Corp now owns 85,929 shares of the company's stock worth $919,000 after acquiring an additional 66,429 shares in the last quarter. Wells Fargo & Company MN increased its position in CapsoVision by 66.4% during the 4th quarter. Wells Fargo & Company MN now owns 6,287 shares of the company's stock valued at $67,000 after purchasing an additional 2,508 shares during the period. Finally, Deutsche Bank AG bought a new stake in shares of CapsoVision in the 4th quarter valued at about $47,000. CapsoVision Company Profile (Get Free Report)CapsoVision, Inc NASDAQ: CV is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out. In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.Read MoreFive stocks we like better than CapsoVisionThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in CapsoVision Right Now?Before you consider CapsoVision, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CapsoVision wasn't on the list.While CapsoVision currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here